Christopher B. Hansen
( out of 655 reviews )

Christopher B. Hansen, MD

Languages spoken: English, French

Clinical Locations

Midvalley Health Center

Murray
801-581-2955

University of Utah Hospital

Dermatology, Area E
Salt Lake City
801-581-2955

  • Christopher B. Hansen, MD has specialized expertise in the evaluation and treatment of rheumatic skin diseases such as lupus erythematosus, dermatomyositis, and scleroderma. He is board certified in Dermatology. Dr. Hansen’s main clinical focus is the medical management of connective tissue diseases that involve the skin as well as common skin disorders such as acne, rashes, and skin cancer. Dr. Hansen runs the UVA-1 phototherapy program in the Department of Dermatology. UVA-1 phototherapy is primarily used to treat patients with sclerosing skin disorders like morphea.

    Specialties

    Board Certification

    American Board of Dermatology (Dermatology)

    Patient Rating

    5.0 /5
    ( out of 655 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    February 29, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Christopher B. Hansen answered all my questions completely and too the time and effort necessary to fully explain all procedures.

    February 29, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Hansen is the best! He makes us feel comfortable and explains everything so we understand. We trust him completely to help resolve our issues.

    February 27, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    I really like Dr. Hansen. He has provided great care to me for years.

    February 27, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Doctor Hansen is top notch! Such a great person!

    February 23, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Squeezed me in on short notice when I needed it

    February 21, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Best dermatologist!!! So caring and takes time to explain everything!

    February 17, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr Hansen is great! He is so good at what he does and makes me feel very comfortable in the care I am given

    February 16, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Professional and friendly.

    February 15, 2024
    UNIVERSITY OF UTAH MIDVALLEY HEALTH CENTER

    Dr. Hansen takes as much time as needed to discuss my concerns and address issues. He never seems rushed and is friendly and professional.

    See More Patient Comments

  • Christopher B. Hansen, MD has specialized expertise in the evaluation and treatment of rheumatic skin diseases such as lupus erythematosus, dermatomyositis, and scleroderma. He is board certified in Dermatology. Dr. Hansen’s main clinical focus is the medical management of connective tissue diseases that involve the skin as well as common skin disorders such as acne, rashes, and skin cancer. Dr. Hansen runs the UVA-1 phototherapy program in the Department of Dermatology. UVA-1 phototherapy is primarily used to treat patients with sclerosing skin disorders like morphea.

    Board Certification and Academic Information

    Academic Departments Dermatology -Primary
    Board Certification
    American Board of Dermatology (Dermatology)

    Education history

    Chief Resident Dermatology - University of Texas Southwestern Chief Resident
    Dermatology - University of Texas Southwestern Medical School Resident
    Internship Internal Medicine - University of Utah School of Medicine Intern
    Dermatology - University of Utah - Dermatology Research Fellow
    Professional Medical Medicine - University of Utah M.D.
    French - University of Utah B.A.

    Selected Publications

    Journal Article

    1. Marcelus C, Jimenez A, Zussman J, Hansen CB, Sontheimer RD (2022). Questions raised by a case of adult-onset linear nodular scleroderma. Dermatol Online J, 28(5). (Read full article)
    2. Overbury RS, Stoddard GJ, Pupaibool J, Hansen CB, Lebiedz-Odrobina D (2021). The effect of an electronic medical record intervention on hydroxychloroquine prescribing habits and surveyed providers' opinions of the 2016 American Academy of Ophthalmology guidelines in the rheumatology and dermatology practices of an academic institutionle. BMC Health Serv Res, 21(1), 913. (Read full article)
    3. Beshay A, Zussman J, Hansen C (2020). Recurrent erythematous patch on the upper arm. JAAD Case Rep, 6(12), 1214-1216. (Read full article)
    4. Winchester D, Duffin KC, Hansen C (2012). Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus, 21(9), 1007-10. (Read full article)
    5. Hansen CB, Dahle KW (2012). Cutaneous lupus erythematosus. Dermatol Ther, 25(2), 99-111. (Read full article)
    6. Gammon B, Hansen C, Costner MI (2011). Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus. J Am Acad Dermatol, 65(4), 717-721.e2. (Read full article)
    7. Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD (2011). A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol, 164(3), 465-72. (Read full article)
    8. Hansen CB, Callen JP (2010). Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea/scleroderma. Dermatol Ther, 23(4), 341-9. (Read full article)

    Case Report

    1. Shah A, Bowen A, Hansen C (2020). Multifocal periungual granulation tissue related to ibrutinib therapy. JAAD Case Rep, 6(2), 149-151. (Read full article)

    Letter

    1. Westerdahl S, Hull CM, Clarke JT, Hansen CB, Rhoads JLW (2020). A single-center, retrospective record review of malignancy prevalence in patients with dermatomyositis with anti-transcription intermediary factor 1γ antibodies via line immunoassay versus immunoprecipitation. [Letter to the editor]. J Am Acad Dermatol, 84(2), 559-561. (Read full article)
    2. Gonzalez CD, Hansen C, Clarke JT (2019). Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study. [Letter to the editor]. J Am Acad Dermatol, 81(3), 859-860. (Read full article)

  • News & Podcasts